Cervilenz Inc. is exhibiting at the 59th Annual Clinical Meeting (ACM) of The American College of Obstetricians and Gynecologists from May 2nd to May 4th, 2011 in Washington D.C. Cervilenz Inc. can be found at Booth #2528.

CerviLenz® measures cervical length during pregnancy. A short cervix is a powerful predictor of preterm birth risk. This simple tool gives obstetricians and midwives a quick, easy way to measure the cervix – in the office, clinic, or hospital.

“It’s been a busy year since we previewed CerviLenz at the 2010 ACM, so we’re excited to be back and to share all the CerviLenz news,” said Dean Koch, President and CEO of Cervilenz Inc. “Across the country, Maternal-Fetal Medicine specialists, obstetricians, and midwives are excited to see this new device and recognize its clinical value.”

Over 500,000 babies are born prematurely every year in the United States. Prematurity affects 12% of pregnancies and is the leading cause of infant morbidity and mortality. Women with a short cervix are at high risk of preterm birth.

After decades of research around the world, there is finally an evidence based intervention to prevent preterm birth. A study published last month reported a 45% reduction in preterm birth for women with a mid-gestation short cervix (10-20 mm) treated with Prochieve® 8%, a vaginal progesterone gel. Experts echo the study’s conclusion that these results create a need for universal cervical length assessment of all pregnant women for short cervix so that high risk women can be treated – since doing so will bring dramatic reductions in the number of babies born prematurely.

Dr. Michael Ross – Medical Director of Cervilenz Inc. and a practicing Maternal-Fetal Medicine specialist – said, “The recent advances in progesterone therapy to prevent preterm birth represent a milestone in obstetrics. Transvaginal ultrasound is the gold standard for cervical length measurement, so all pregnant women should get this exam mid-gestation. But to identify and monitor all patients with a short cervix, there is a need for multiple cervical measurements during pregnancy. The limited availability of transvaginal ultrasound, which requires a highly trained examiner, cannot meet this need alone. That’s where CerviLenz comes in. CerviLenz will play an important role in making sure the full impact of progesterone therapy is realized for moms and babies.”

About Cervilenz Inc.

Founded in 2008, Cervilenz Inc. is the manufacturer and distributor of CerviLenz® – an innovative medical device that measures vaginal cervical length during pregnancy. Dedicated to helping reduce the rate of premature birth globally, Cervilenz Inc. donates a portion of revenue to charitable organizations that advance maternal and fetal health. The company headquarters is in the beautiful village of Chagrin Falls, a suburb of Cleveland, Ohio. CerviLenz is manufactured in Ohio for sale worldwide.

100 N. Main Street, Suite 300
Chagrin Falls, OH 44022

This release was published on openPR.